FULC

Fulcrum Therapeutics Stock Analysis

AI Rating

Fair
  • Quality2/10
  • Growth↓ 0/10
  • Momentum↑ 8/10
Fulcrum Therapeutics sales and earnings growth
FULC Growth
Low
  • Revenue Y/Y↓ -100.00%
  • EPS Y/Y↓ -293.10%
  • FCF Y/Y↓ -591.31%
Fulcrum Therapeutics gross and profit margin trends
FULC Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -38.20%
Fulcrum Therapeutics net debt vs free cash flow
FULC Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Fulcrum Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗